Despite Recent Bad News, Here's Why CRISPR Is Primed to Explode
CRISPR Therapeutics' (NASDAQ: CRSP) stock took a hard hit when it disclosed on Oct. 21 that a patient in its Carbon phase 1 clinical trial for relapsed non-Hodgkin's lymphoma died unexpectedly earlier this month. But this unfortunate news doesn't diminish the company's immense potential stemming from its advanced gene-editing technology. Nor will it throw any of CRISPR's clinical trials off track. In fact, with these preliminary results in hand, CRISPR has two powerful things in its favor that investors should know.
First, the company now has clinical proof-of-concept for its leading oncology pipeline program. Though one patient died, others in the trial experienced positive effects from the therapy. Second, its cell therapy manufacturing methodology has been validated in a real-world setting. Both of these developments suggest that the largest takeaway from the trial's preliminary results is that investors should be ready to buy the dip and settle in for the long term. Let's take a closer look at what happened in the trial and what the company aims to do with its development pipeline.
Image source: Getty Images.
Source Fool.com